IL11RA

Across TCGA pan-cancer cohorts, IL11RA Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated IL11RA data layer compared with 24 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher IL11RA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IL11RA expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BRCA, THCA, and HNSC are the cancer types where IL11RA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	III,IV	0.140	0.833	<.001	24	view →
THCA	DFS	Median	All	0.061	0.828	<.001	18	view →
HNSC	OS	Median	III,IV	0.010	0.746	<.001	12	view →
SKCM	OS	Median	All	0.534	0.875	.002	7	view →
BLCA	DFS	Median	All	1.000	0.330	.043	4	view →
MESO	OS	Median	II,III,IV	0.180	0.560	.046	3	view →
LUAD	OS	Median	All	0.276	0.697	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

IL11RA–BRCA (OS)

Open the BRCA breakdown →